# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 12b-25

## NOTIFICATION OF LATE FILING

☐ Transition Report on Form 10-K

For Period Ended:

OMB	<b>APPRO</b>	VAL

OMB Number: 3235-0058 Expires: February 28, 2022

Estimated average burden hours per response ... 2.50

SEC FILE NUMBER 001-38185

CUSIP NUMBER

☐ Transition Report on Form 20-F				
☐ Transition Report on Form 11-K				
☐ Transition Report on Form 10-Q				
☐ Transition Report on Form N-SAR				
For the Transition Period Ended:				
Read Instruction (on back page) Before Preparing Form. Please Print or Type.  Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.				
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:				
PART I — REGISTRANT INFORMATION				
Pressure BioSciences, Inc.				
Full Name of Registrant				
Former Name if Applicable				
14 Norfolk Avenue				
Address of Principal Executive Office (Street and Number)				
South Easton, MA 02375				
City, State and Zip Code				

□ Form 10-K □ Form 20-F □ Form 11-K ⊠ Form 10-Q □ Form 10-D □ Form N-SAR □ Form N-CSR

September 30, 2021

### PART II — RULES 12b-25(b) AND (c)

(Check one):

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

### PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

PRESSURE BIOSCIENCES, INC. (the "Registrant") was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the "Quarterly Report") by the November 15, 2021 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the period ended September 30, 2021 to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date.

Name and telephone number of person to contact in regard to this no	otification	
Richard T. Schumacher	(508)	230-1828
(Name)	(Area Code)	(Telephone Number)
1 1	Č	1 ,
Is it anticipated that any significant change in results of operations included in the subject report or portion thereof?	from the corresponding period for the last fisc	al year will be reflected by the earnings statements to be $Yes \;\square\; No \;\boxtimes$
If so, attach an explanation of the anticipated change, both narrative be made.	ly and quantitatively, and, if appropriate, state the	he reasons why a reasonable estimate of the results cannot
	· · · · · · · · · · · · · · · · · · ·	
caused this notification to be signed on its behalf by the undersigned	hereunto duly authorized.	
vember 16, 2021	By: /s/Richard T. Schumach Name: Richard T. Schumach Title: Chief Executive Office	r
	Richard T. Schumacher (Name)  Have all other periodic reports required under Section 13 or 15(d) or preceding 12 months or for such shorter period that the registrant w  Is it anticipated that any significant change in results of operations included in the subject report or portion thereof?  If so, attach an explanation of the anticipated change, both narrative be made.  PR (Name)	(Name)  (Name)  (Area Code)  Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If an Is it anticipated that any significant change in results of operations from the corresponding period for the last fisc included in the subject report or portion thereof?  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the made.  PRESSURE BIOSCIENCES, INC. (Name of Registrant as Specified in Charter)  caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.  Vember 16, 2021  By: /s/ Richard T. Schumacher Richard Richard T. Schumacher Richard T. Schumacher Richard R